Chapter: 1 INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models

Chapter: 2 EXECUTIVE SUMMARY

2.1. CXO PERSPECTIVE

Chapter: 3 MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS

3.2.1. Top investment pockets
3.2.2. Top winning strategies

3.3. MARKET SHARE ANALYSIS, 2016
3.4. PORTER’S FIVE FORCES ANALYSIS
3.5. MARKET DYNAMICS

3.5.1. Drivers
3.5.2. Restraints
3.5.3. Opportunities

Chapter: 4 ESMOLOL HYDROCHLORIDE MARKET, BY INDICATION

4.1. OVERVIEW

4.1.1. Market size and forecast

4.2. SUPRAVENTRICULAR TACHYCARDIA OR NONCOMPENSATORY SINUS TACHYCARDIA

4.2.1. Key market trends
4.2.2. Growth factors and opportunities
4.2.3. Market size and forecast

4.3. INTRAOPERATIVE & POSTOPERATIVE TACHYCARDIA

4.3.1. Key market trends
4.3.2. Growth factors and opportunities
4.3.3. Market size and forecast

4.4. HYPERTENSION

4.4.1. Key market trends
4.4.2. Growth factors and opportunities
4.4.3. Market size and forecast

Chapter: 5 ESMOLOL HYDROCHLORIDE MARKET, BY END USER

5.1. OVERVIEW

5.1.1. Market size and forecast

5.2. HOSPITALS

5.2.1. Market size and forecast

5.3. CLINICS

5.3.1. Market size and forecast

5.4. RESEARCH INSTITUTES

5.4.1. Market size and forecast

5.5. OTHERS

5.5.1. Market size and forecast 

Chapter: 6 ESMOLOL HYDROCHLORIDE MARKET, BY REGION

6.1. OVERVIEW
6.2. NORTH AMERICA

6.2.1. Key market trends
6.2.2. Key growth factors and opportunities
6.2.3. Market size and forecast

6.2.3.1. U.S. market size and forecast
6.2.3.2. Canada market size and forecast
6.2.3.3. Mexico market size and forecast

6.2.4. North America Esmolol Hydrochloride Market by Indication
6.2.5. North America Esmolol Hydrochloride Market by End User

6.3. EUROPE

6.3.1. Key market trends
6.3.2. Key growth factors and opportunities
6.3.3. Market size and forecast

6.3.3.1. Germany market size and forecast
6.3.3.2. France market size and forecast
6.3.3.3. UK market size and forecast
6.3.3.4. Italy market size and forecast
6.3.3.5. Spain market size and forecast
6.3.3.6. Rest of Europe market size and forecast

6.3.4. Europe Esmolol Hydrochloride Market by Indication
6.3.5. Europe Esmolol Hydrochloride Market by End User

6.4. ASIA-PACIFIC

6.4.1. Key market trends
6.4.2. Key growth factors and opportunities
6.4.3. Market size and forecast

6.4.3.1. Japan market size and forecast
6.4.3.2. China market size and forecast
6.4.3.3. Australia market size and forecast
6.4.3.4. India market size and forecast
6.4.3.5. South Korea market size and forecast
6.4.3.6. Rest of Asia-Pacific market size and forecast

6.4.4. Asia-Pacific Esmolol Hydrochloride Market by Indication
6.4.5. Asia-Pacific Esmolol Hydrochloride Market by End User

6.5. LAMEA

6.5.1. Key market trends
6.5.2. Key growth factors and opportunities
6.5.3. Market size and forecast

6.5.3.1. Brazil market size and forecast
6.5.3.2. Saudi Arabia market size and forecast
6.5.3.3. South Africa market size and forecast
6.5.3.4. Rest of LAMEA market size and forecast

6.5.4. LAMEA Esmolol Hydrochloride Market by Indication
6.5.5. LAMEA Esmolol Hydrochloride Market by End User

Chapter: 7 COMPANY PROFILES

7.1. APP PHARMACEUTICALS MANUFACTURING, LLC

7.1.1. Operating business segments
7.1.2. Business performance
7.1.3. Key strategic moves and developments

7.2. HIKMA PHARMACEUTICALS PLC

7.2.1. Operating business segments
7.2.2. Business performance
7.2.3. Key strategic moves and developments

7.3. BAXTER INTERNATIONAL INC.

7.3.1. Operating business segments
7.3.2. Business performance
7.3.3. Key strategic moves and developments

7.4. GENERAL INJECTABLES AND VACCINES, INC.

7.4.1. Operating business segments
7.4.2. Business performance
7.4.3. Key strategic moves and developments

7.5. BAYER AG

7.5.1. Operating business segments
7.5.2. Business performance
7.5.3. Key strategic moves and developments

7.6. BIONICHE PHARMA USA INC.

7.6.1. Operating business segments
7.6.2. Business performance
7.6.3. Key strategic moves and developments